Declaration of interest
G. Trifirò has participated in advisory boards on topics not related to this paper for Sandoz, Hospira, Sanofi, Biogen, Ipsen, Shire and is a consultant for Otsuka; G. Trifirò is also principal investigator of observational studies funded by Amgen, AstraZeneca, Daiichi Sankyo, and IBSA through the University of Messina, and scientific coordinator of the Masters program ‘Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real world data evaluations’ at University of Messina which is partly funded by several pharmaceutical companies.
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.